Professor of Radiation Oncology, Institute for Academic Medicine
Full Member, Research Institute
Weill Cornell Medical College
Dr. Teh is a professor and vice chair of the Department of Radiation Oncology at Houston Methodist Hospital and Weill Medical School of Cornell. Dr. Teh has contributed significantly to the field of radiation oncology – encompassing radiotherapy technology, radiation physics, molecular radiobiology and the translation of advances in these areas to clinical use. He has been instrumental in pioneering new technology in radiation oncology including APBI (accelerated partial breast irradiation), IMRT (intensity-modulated radiation therapy), IGRT (image-guided radiation therapy), SBRT (stereotactic body radiation therapy), SRS (stereotactic radiosurgery), brachytherapy as well as combined radiotherapy and gene therapy. Dr. Teh treated the first breast cancer patient in Houston with multi-lumen catheter (Contura) high dose rate brachytherapy for partial breast irradiation. This is a short course of five days irradiation, as compared to the conventional six weeks irradiation for breast cancer. Partial breast irradiation is a novel approach to spare more normal tissues.
Dr. Teh earned his medical degree from the University of Queensland in Queensland, Australia. He completed his Radiation Oncology residency, training and fellowship in IMRT at the Baylor College of Medicine in Houston, Texas. Dr. Teh is active in ASTRO (American Society of Therapeutic Radiology and Oncology), RSNA (Radiological Society of North America and ARS (American Radium Society). He is the principal investigator for RTOG (Radiation Therapy Oncology Group) at Houston Methodist Hospital. Dr. Teh has published more than 100 peer-reviewed articles on topics such as IMRT for breast cancer, editorials, 15 book chapters and a textbook on PET-CT in radiotherapy. He plays an important role in breast cancer patient care, clinical research and the education of residents and students.
Dr. Teh’s research focuses on the treatment of genito-urinary malignancies and unlocking the myth of radio-resistance in cancers especially renal cell carcinoma. Other research interests include Intensity modulated radiation therapy (IMRT) for prostate cancer, head and neck cancer, central nervous system tumor, pediatric cancer and breast cancer, stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), stereotactic radiation therapy (SRT) and image-guided radiation therapy (IGRT), brachytherapy for prostate cancer, breast cancer and endobronchial tumors, SRS and SBRT for primary and metastatic renal cell carcinoma as well as hepatocellular carcinoma, the role of combined radiotherapy and gene therapy for cancers including prostate cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer and head and neck cancer, combining targeted therapy (AKT-inhibitor, mTOR inhibitor, tyrosine kinase inhibitor) with radiotherapy for cancer treatment, and combining oncolytic virus with radiotherapy in overcoming radio-resistant tumors in oncology.